Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07324330

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.

The aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.

Eighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the "Deutsches Zentrum für Neurodegenerative Erkrankungen" (DZNE) Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, magnetic resonance imaging (MRI) and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https://clinicaltrials.gov/study/NCT06993142). In addition, selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-are planned to be synthesized into a meta-analysis.

Recruiting

Interested in participating?

Request Info

Key information

About this study

α-Synucleinopathies are the second most common group of neurodegenerative diseases after Alzheimer's disease (AD). Their prevalence is expected to increase significantly, with more than 12 million people worldwide likely to be affected by 2040. Clinical manifestations include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). These diseases are characterized by neuronal inclusions of α-synuclein aggregates and Lewy bodies, which lead to premature aging of the brain. In addition to motor impairments, cognitive decline is a central element of non-motor symptoms, which not only occurs in DLB but also affects up to 80% of people with PD. Cognitive deficits can often occur in the early stages of the disease and significantly impair social functioning and quality of life. Despite their high prevalence, there are currently only a few therapeutic approaches for treating cognitive impairments in α-synucleinopathies. Therefore, easily accessible, early preventive interventions are crucial to counteract cognitive decline.

Isolated REM sleep behavior disorder (iRBD) is considered an early sign of α-synucleinopathy and can be reliably diagnosed using video polysomnography. Over 90% of individuals with iRBD develop either PD or DLB within 20 years of diagnosis, with an approximately equal distribution between the two entities. It is noteworthy that executive functions can often already be impaired in iRBD, which is associated with an increased risk of early conversion to PD or DLB. Thus, iRBD represents a phase of early neurodegeneration in which there is a high risk of cognitive decline. For this reason, individuals with iRBD are a particularly suitable target group for investigating the effects of lifestyle modifications that could slow the progression of the disease at an early stage.

Increasing physical activity could offer a promising way to slow the progression of neurodegenerative processes in the early stages of α-synucleinopathies. Since motor impairments are a central feature of PD and DLB, many affected individuals-even in the early stages of the disease-do not achieve the recommended level of physical activity. Studies on increasing physical activity have shown that physical training has positive effects on cerebrovascular function and cognitive performance, both in healthy aging and in various neurodegenerative diseases. For α-synucleinopathies in particular, there is evidence from animal models, observational studies, and clinical trials with up to six months of follow-up that physical activity may have disease-modifying effects. A recent meta-analysis in PD found that various interventions to increase physical activity have moderate effects on global cognition and even strong effects on executive functions. Therefore, promoting a more active lifestyle could be a promising strategy to positively influence the early course of α-synucleinopathies. Motivational mobile apps offer a novel way to increase physical activity, as they can be used completely independently, allowing for a high degree of scalability of the intervention.

Derivation of research questions

The following key questions will be addressed in the research project:

  • Can the progression of motor and cognitive changes in individuals with iRBD be influenced by increasing physical activity?
  • Does this intervention also affect biological and imaging markers of pathological brain aging?
  • Does this intervention also have an effect on healthy older people?

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

iRBD:

  • Age: 50-80 years
  • Polysomnographically confirmed diagnosis of iRBD
  • Maximum of 120 minutes of sports/outdoor activities per day
  • Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
  • Basic smartphone skills
  • Sufficient knowledge of German (native language, C1 or C2)
  • Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)
  • Consent to be informed of any additional findings

Healthy controls:

  • Age: 50-80 years
  • Maximum of 120 minutes of sports/outdoor activities per day
  • Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase
  • Basic smartphone skills
  • Sufficient knowledge of German (native language, C1 or C2)
  • Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)
  • Consent to be informed of any additional findings

Exclusion criteria

iRBD:

  • Relevant cardiovascular diseases
  • Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
  • Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
  • Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)

Healthy controls:

  • Relevant cardiovascular diseases
  • Problems with dexterity or cognitive impairments that make it difficult to use a smartphone
  • Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study
  • Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)
  • clinically diagnosed iRBD

Treatment and study plan

Increase of physical activity volume and intensity with the use of a motivational smartphone application

Behavioral

A motivational smartphone application will be available for all participants using their own smartphone: the Alpha-Fit app, comparable to the SLOW-SPEED app (https://clinicaltrials.gov/study/NCT06993142). The Alpha-Fit app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (12 months) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting moderate-to-vigorous physical activity (MVPA) relative to baseline level).

Other names: Motivational movement intervention

Primary outcomes

  1. Cognitive Performance: Change in mild cognitive impairment (MCI) in PD Level II Criteria

    Time frame: 12 months

    Change in cognitive performance between the start of the study (baseline) and the time after the intervention (after 12 months of intervention), measured as the global mean of the results from a neuropsychological test battery according to MCI in PD Level II criteria.

    Executive functions:

    • semantic word fluency
    • set-shifting abilities
    • inhibition
    • logical thinking

    Visual cognitive abilities:

    • spatial perception
    • working memory performance
    • processing speed
    • attention

    Memory functions:

    • verbal memory
    • visuospatial memory

    Linguistic abilities:

    • naming semantic
    • abstract thinking

Secondary outcomes

  1. Motor functions: Change in Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III

    Time frame: 12 months

    Change in score which ranges from 0 to 108. Higher score indicates greater motor impairment.

  2. Motor functions: Change Perdue-Pegboard-Test

    Time frame: 12 months

    Change in score. Higher scores indicates better manual dexterity and hand coordination.

  3. Motor functions: Change in digital testing outcomes

    Time frame: 12 months

    Change in digital testing assessment, funded by the European Research Council (ERC) (https://cordis.europa.eu/project/id/101169580).

  4. Change in body composition

    Time frame: 12 months

    Change in body composition measured through MRI sequences and bio-electric impedance analysis.

  5. Sleep behavior: Change in subjective sleep quality

    Time frame: 12 months

    Change in Pittsburgh Sleep Quality Index (PSQI), with scores between 0 and 21, higher scores indicate worse sleep.

  6. Sleep behavior: Change in Polysomnography (PSG) read-outs

    Time frame: 12 months

    Change in PSG read-outs.

  7. Change in blood-based markers for metabolism.

    Time frame: 12 months

    Change found in biomarkers in plasma, serum and peripheral blood mononuclear cells (PBMCs).

  8. Change in blood-based markers for neurodegeneration.

    Time frame: 12 months

    Change found in biomarkers in plasma, serum and PBMCs

  9. Change in blood-based markers for inflammation.

    Time frame: 12 months

    Change found in biomarkers in plasma, serum and PBMCs

  10. Cognitive performance: Change in performance in digital app

    Time frame: 12 months

    Change in performance in the https://www.neuronation.com/ app. Will be measured in 2-week intervals.

  11. Change in Quantitative MRI Measures of Brain Structure and Function

    Time frame: 12 months

    Change from baseline to 12 months in MRI-derived quantitative measures of brain structure and function, including resting-state functional magnatic resonance imaging (fMRI), T1-weighted structural measures, fluid-attenuated inversion recovery (FLAIR) based measures, quantitative susceptibility mapping (QSM) metrics, and neuromelanin-sensitive MRI signal measures.

Study contacts

Contact information is provided by the study sponsor or research team.

Emily L Fitzgibbon, M.Sc.

CONTACT

[email protected]

Martin M Rodemann

CONTACT

[email protected]

+49 0228 287 - 19436

Sponsors and collaborators

Lead sponsor

University Hospital, Bonn

Other

Collaborators

  • IJsfontein B.V., Netherlands
  • Medical University Innsbruck
  • Parkinson Stiftung
  • Radboud University Medical Center
  • Synaptikon GmbH

Registry information

Acronym: ALPHA-FIT

Important dates

Study start
2025
Primary completion
2028
Study completion
2029
First posted
Jan 7, 2026
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.